期刊
ANNUAL REVIEW OF MEDICINE, VOL 66
卷 66, 期 -, 页码 17-29出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-062613-093128
关键词
diabetes; oncology; epidemiology; clinical trials
资金
- Scottish Government-sponsored Chief Scientist Office Clinical Academic Fellowship
Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据